Renaissance Capital logo

AI drug discovery biotech Recursion Pharmaceuticals sets terms for $306 million IPO

April 12, 2021

Recursion Pharmaceuticals, a Phase 2-ready biotech using AI to develop therapies for various indications, announced terms for its IPO on Monday.

The Salt Lake City, UT-based company plans to raise $306 million by offering 18 million shares at a price range of $16 to $18. Insiders Baillie Gifford and Mubadala Investment intend to purchase up to $125 million worth of shares in the offering. At the midpoint of the proposed range, Recursion Pharmaceuticals would command a market value of $3 billion.

Central to Recursion's mission is the Recursion Operating System, which combines an advanced infrastructure layer to generate proprietary biological and chemical datasets, and the Recursion Map, a suite of custom software, algorithms, and machine learning tools that the company uses to explore foundational biology and navigate to new biological insights. While the company is advancing 37 programs, its most advanced programs include one candidate targeting oncology and three targeting rare genetic disorders, all of which are expected to enter Phase 2 or 2/3 trials within the next four to five quarters.

Recursion Pharmaceuticals was founded in 2013 and booked $4 million in revenue for the 12 months ended December 31, 2020. It plans to list on the Nasdaq under the symbol RXRX. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink, Allen & Company and KeyBanc Capital Markets are the joint bookrunners on the deal. It is expected to price during the week of April 12, 2021.